vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Significant Drop in Short Interest

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 24,100 shares, a decrease of 13.6% from the February 13th total of 27,900 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 13,300 shares, the days-to-cover ratio is currently 1.8 days.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. StockNews.com started coverage on vTv Therapeutics in a research report on Wednesday. They issued a "sell" rating on the stock. Alliance Global Partners started coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a "buy" rating and a $35.00 target price for the company.

Hedge Funds Weigh In On vTv Therapeutics

A number of hedge funds have recently made changes to their positions in VTVT. FMR LLC purchased a new position in shares of vTv Therapeutics in the third quarter valued at $2,402,000. JPMorgan Chase & Co. purchased a new position in vTv Therapeutics in the 4th quarter valued at about $25,000. Finally, Geode Capital Management LLC grew its stake in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 1,327 shares in the last quarter. Institutional investors and hedge funds own 17.51% of the company's stock.

Remove Ads

vTv Therapeutics Stock Performance

NASDAQ VTVT traded down $0.96 during mid-day trading on Friday, reaching $16.64. 20,028 shares of the stock were exchanged, compared to its average volume of 23,070. The stock has a market capitalization of $53.08 million, a PE ratio of -3.67 and a beta of 1.07. vTv Therapeutics has a 1-year low of $12.12 and a 1-year high of $29.85. The business's fifty day simple moving average is $16.97 and its 200 day simple moving average is $15.44.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32. The business had revenue of $0.02 million for the quarter.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.